386 related articles for article (PubMed ID: 29045336)
1. Bile acid receptors and the kidney.
Herman-Edelstein M; Weinstein T; Levi M
Curr Opin Nephrol Hypertens; 2018 Jan; 27(1):56-62. PubMed ID: 29045336
[TBL] [Abstract][Full Text] [Related]
2. FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity.
Wang XX; Wang D; Luo Y; Myakala K; Dobrinskikh E; Rosenberg AZ; Levi J; Kopp JB; Field A; Hill A; Lucia S; Qiu L; Jiang T; Peng Y; Orlicky D; Garcia G; Herman-Edelstein M; D'Agati V; Henriksen K; Adorini L; Pruzanski M; Xie C; Krausz KW; Gonzalez FJ; Ranjit S; Dvornikov A; Gratton E; Levi M
J Am Soc Nephrol; 2018 Jan; 29(1):118-137. PubMed ID: 29089371
[TBL] [Abstract][Full Text] [Related]
3. Bile acid signaling in renal water regulation.
Li S; Li C; Wang W
Am J Physiol Renal Physiol; 2019 Jul; 317(1):F73-F76. PubMed ID: 31091123
[TBL] [Abstract][Full Text] [Related]
4. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism.
Pathak P; Liu H; Boehme S; Xie C; Krausz KW; Gonzalez F; Chiang JYL
J Biol Chem; 2017 Jun; 292(26):11055-11069. PubMed ID: 28478385
[TBL] [Abstract][Full Text] [Related]
5. A dual agonist of farnesoid X receptor (FXR) and the G protein-coupled receptor TGR5, INT-767, reverses age-related kidney disease in mice.
Wang XX; Luo Y; Wang D; Adorini L; Pruzanski M; Dobrinskikh E; Levi M
J Biol Chem; 2017 Jul; 292(29):12018-12024. PubMed ID: 28596381
[TBL] [Abstract][Full Text] [Related]
6. Bile acid receptors in non-alcoholic fatty liver disease.
Li Y; Jadhav K; Zhang Y
Biochem Pharmacol; 2013 Dec; 86(11):1517-24. PubMed ID: 23988487
[TBL] [Abstract][Full Text] [Related]
7. Investigation on bile acid receptor regulators. Discovery of cholanoic acid derivatives with dual G-protein coupled bile acid receptor 1 (GPBAR1) antagonistic and farnesoid X receptor (FXR) modulatory activity.
Sepe V; Renga B; Festa C; Finamore C; Masullo D; Carino A; Cipriani S; Distrutti E; Fiorucci S; Zampella A
Steroids; 2016 Jan; 105():59-67. PubMed ID: 26607331
[TBL] [Abstract][Full Text] [Related]
8. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR.
Jadhav K; Xu Y; Xu Y; Li Y; Xu J; Zhu Y; Adorini L; Lee YK; Kasumov T; Yin L; Zhang Y
Mol Metab; 2018 Mar; 9():131-140. PubMed ID: 29361497
[TBL] [Abstract][Full Text] [Related]
9. Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease.
Chávez-Talavera O; Tailleux A; Lefebvre P; Staels B
Gastroenterology; 2017 May; 152(7):1679-1694.e3. PubMed ID: 28214524
[TBL] [Abstract][Full Text] [Related]
10. Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease.
Halilbasic E; Fuchs C; Traussnigg S; Trauner M
Dig Dis; 2016; 34(5):580-8. PubMed ID: 27332721
[TBL] [Abstract][Full Text] [Related]
11. Intestinal Farnesoid X Receptor and Takeda G Protein Couple Receptor 5 Signaling in Metabolic Regulation.
Chiang JY; Pathak P; Liu H; Donepudi A; Ferrell J; Boehme S
Dig Dis; 2017; 35(3):241-245. PubMed ID: 28249273
[TBL] [Abstract][Full Text] [Related]
12. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy.
Chiang JYL; Ferrell JM
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G554-G573. PubMed ID: 31984784
[TBL] [Abstract][Full Text] [Related]
13. Gluco-Metabolic Effects of Pharmacotherapy-Induced Modulation of Bile Acid Physiology.
Brønden A; Knop FK
J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31630179
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effects of bile acid receptor agonists in pulmonary disease models.
Comeglio P; Morelli A; Adorini L; Maggi M; Vignozzi L
Expert Opin Investig Drugs; 2017 Nov; 26(11):1215-1228. PubMed ID: 28949776
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression.
Erice O; Labiano I; Arbelaiz A; Santos-Laso A; Munoz-Garrido P; Jimenez-Agüero R; Olaizola P; Caro-Maldonado A; Martín-Martín N; Carracedo A; Lozano E; Marin JJ; O'Rourke CJ; Andersen JB; Llop J; Gómez-Vallejo V; Padro D; Martin A; Marzioni M; Adorini L; Trauner M; Bujanda L; Perugorria MJ; Banales JM
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1335-1344. PubMed ID: 28916388
[TBL] [Abstract][Full Text] [Related]
16. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders.
Fiorucci S; Mencarelli A; Palladino G; Cipriani S
Trends Pharmacol Sci; 2009 Nov; 30(11):570-80. PubMed ID: 19758712
[TBL] [Abstract][Full Text] [Related]
17. A role of the bile salt receptor FXR in atherosclerosis.
Hageman J; Herrema H; Groen AK; Kuipers F
Arterioscler Thromb Vasc Biol; 2010 Aug; 30(8):1519-28. PubMed ID: 20631352
[TBL] [Abstract][Full Text] [Related]
18. Chemistry and Pharmacology of GPBAR1 and FXR Selective Agonists, Dual Agonists, and Antagonists.
De Marino S; Festa C; Sepe V; Zampella A
Handb Exp Pharmacol; 2019; 256():137-165. PubMed ID: 31201554
[TBL] [Abstract][Full Text] [Related]
19. New insights in the multiple roles of bile acids and their signaling pathways in metabolic control.
de Boer JF; Bloks VW; Verkade E; Heiner-Fokkema MR; Kuipers F
Curr Opin Lipidol; 2018 Jun; 29(3):194-202. PubMed ID: 29553998
[TBL] [Abstract][Full Text] [Related]
20. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy.
Jiang T; Wang XX; Scherzer P; Wilson P; Tallman J; Takahashi H; Li J; Iwahashi M; Sutherland E; Arend L; Levi M
Diabetes; 2007 Oct; 56(10):2485-93. PubMed ID: 17660268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
